Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

76 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-31

Study Completion Date

2018-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

NCT01103323

Metastatic Colorectal Cancer

COMPLETED PHASE3

Safety and Effectiveness of Regorafenib

NCT02042144

Neoplasms

COMPLETED

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

NCT01959269

Colorectal Neoplasm

COMPLETED

Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

NCT02465502

Colorectal Neoplasms

COMPLETED PHASE2

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States

NCT06029010

Metastatic Colorectal Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regorafenib_DoT<4 months

DoT \< 4 months

Regorafenib (Stivarga, BAY73-4506)

Intervention Type DRUG

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Regorafenib_4 months ≤ DoT < 12 months

4 months ≤ DoT \< 12 months

Regorafenib (Stivarga, BAY73-4506)

Intervention Type DRUG

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Regorafenib_DoT ≥ 12 months

DoT ≥ 12 months

Regorafenib (Stivarga, BAY73-4506)

Intervention Type DRUG

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Regorafenib (Stivarga, BAY73-4506)

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients ≥ 18 years of age.
* Patients who suffer from mCRC and who started treatment with Stivarga between the 1st of July 2015 and 31 July 2017.
* Patients who already received alternative treatment options before Stivarga for the treatment of mCRC or who were not eligible for other treatment options.
* Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1 at start of Stivarga treatment.
* Sufficient kidney, liver and bone marrow function start of Stivarga treatment.
* Life expectancy ≥ 3 months at start of Stivarga treatment

Exclusion Criteria

\- Patients participating in an investigational program/clinical trial with interventions outside of routine clinical practice during the observational period.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No